Wall Street brokerages predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will report ($0.02) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.08) and the highest estimate coming in at $0.03. AVEO Pharmaceuticals reported earnings per share of ($0.05) in the same quarter last year, which would suggest a positive year over year growth rate of 60%. The business is scheduled to report its next quarterly earnings results on Friday, November 8th.

On average, analysts expect that AVEO Pharmaceuticals will report full year earnings of $0.01 per share for the current year, with EPS estimates ranging from ($0.02) to $0.03. For the next year, analysts forecast that the firm will post earnings of ($0.15) per share, with EPS estimates ranging from ($0.19) to ($0.12). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.04. AVEO Pharmaceuticals had a negative net margin of 46.69% and a negative return on equity of 50.69%. The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.78 million.

Several equities research analysts recently issued reports on the stock. HC Wainwright raised shares of AVEO Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $1.00 to $1.75 in a report on Wednesday, September 11th. Piper Jaffray Companies increased their target price on shares of AVEO Pharmaceuticals from $3.00 to $4.00 and gave the stock an “overweight” rating in a report on Tuesday, September 10th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $2.25.

A number of institutional investors have recently added to or reduced their stakes in the stock. HCR Wealth Advisors purchased a new stake in AVEO Pharmaceuticals in the 1st quarter worth approximately $28,000. Cetera Advisor Networks LLC purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter worth approximately $38,000. Anson Funds Management LP purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter worth approximately $33,000. SG Americas Securities LLC purchased a new stake in AVEO Pharmaceuticals in the 1st quarter worth approximately $50,000. Finally, Jane Street Group LLC purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter worth approximately $98,000. 29.55% of the stock is owned by institutional investors.

Shares of NASDAQ AVEO traded down $0.06 during midday trading on Wednesday, hitting $0.99. 2,082,716 shares of the company’s stock traded hands, compared to its average volume of 4,631,126. AVEO Pharmaceuticals has a 1 year low of $0.49 and a 1 year high of $3.59. The stock has a market capitalization of $159.13 million, a price-to-earnings ratio of -5.21 and a beta of 0.74. The company has a debt-to-equity ratio of 6.84, a quick ratio of 2.21 and a current ratio of 2.21. The firm has a fifty day moving average of $0.72 and a 200 day moving average of $0.76.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Recommended Story: What is a Buy-Side Analyst?

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.